Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in black and white hypertensive patients

Clinical Pharmacokinetics

Volumn 52, Issue 9, 2013, Pages 793-803

  Van Rijn Bikker, Petra C ^a   Ackaert, Oliver ^b   Snelder, Nelleke ^b   Van Hest, Reinier M ^a   Ploeger, Bart A ^c   Koopmans, Richard P ^d   Mathôt, Ron A A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LAP and P Consultants   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CAUCASIAN; CIRCADIAN RHYTHM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TRANSPORT; ESSENTIAL HYPERTENSION; ETHNICITY; FEMALE; GASTROINTESTINAL ABSORPTION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ACRYLATES; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; THIOPHENES;

EID: 84883157089     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0073-6     Document Type: Article

References (26)

1. Redon J, Brunner HR, Ferri C, et al. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens Suppl. 2008;26(4):S1-14.
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121-58.
3. Gomez HJ, Cirillo VJ, Sromovsky JA, et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol. 1989;28(4):415-20. (Pubitemid 19269779)
4. MacGregor GA, Banks RA, Markandu ND, et al. Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. Br Med J (Clin Res Ed). 1983;286(6377):1535-8. (Pubitemid 13083602)
5. Hansson L, Zweifler AJ, Julius S, et al. Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response. Int J Clin Pharmacol. 1974;10(2):79-89.
6. Meredith PA. Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. J Hypertens Suppl. 1997;15(5):S27-31.
7. Donnelly R, Elliott HL, Meredith PA, et al. Concentration-effect relationships and individual responses to doxazosin in essential hypertension. Br J Clin Pharmacol. 1989;28(5):517-26. (Pubitemid 19273598)
8. Donnelly R, Elliott HL, Meredith PA, et al. Nifedipine: individual responses and concentration-effect relationships. Hypertension. 1988;12(4):443-9.
9. Donnelly R, Elliott HL, Meredith PA, et al. The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin. Eur J Clin Pharmacol. 1993;44(3):279-82. (Pubitemid 23096158)
10. Ackaert O, Van Rijn-Bikker PC, Snelder N, et al. Population modeling of blood pressure: assessing clinically important factors for cardiovasular disease. PAGE 20 (2011) Abstr 2025. www.page-meeting.org/?abstract=2025.
11. van Rijn-Bikker PC, Mairuhu G, van Montfrans GA, et al. Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. Am J Hypertens. 2009;22(12):1295-302.
12. Li XN, Xu HR, Chen WL, et al. Determination of eprosartan in human plasma and urine by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1-2):47-53.
13. Ferreiros N, Dresen S, Alonso RM, et al. Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression. Ther Drug Monit. 2007;29(6):824-34. (Pubitemid 350190862)
14. Tenero D, Martin D, Ilson B, et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos. 1998;19(6):351-6. (Pubitemid 28393854)
15. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371(9631):2219-21.
16. Chapelsky MC, Martin DE, Tenero DM, et al. A dose proportionality study of eprosartan in healthy male volunteers. J Clin Pharmacol. 1998;38(1):34-9. (Pubitemid 28086721)
17. Tenero DM, Martin DE, Miller AK, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol. 1998;46(3):267-70. (Pubitemid 28404841)
18. Csajka C, Buclin T, Fattinger K, et al. Population pharmacokinetic- pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet. 2002;41(2):137-52. (Pubitemid 34266099)
19. Morsing P, Vauquelin G. How can the differences among AT1-receptor antagonists be explained? Cell Biochem Biophys. 2001;35(1):89-102. (Pubitemid 33612631)
20. Vauquelin G, Van Liefde I, Birzbier BB, et al. New insights in insurmountable antagonism. Fundam Clin Pharmacol. 2002;16(4):263-72. (Pubitemid 35205336)
21. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302(2):237-43.
22. Chapman AB, Schwartz GL, Boerwinkle E, et al. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002;61(3):1047-55. (Pubitemid 34175474)
23. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614-27. (Pubitemid 39390539)
24. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in blacks consensus statement. Hypertension. 2010;56(5):780-800.
25. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.
26. Donnelly R, Elliott HL, Meredith PA. Antihypertensive drugs: individualized analysis and clinical relevance of kinetic-dynamic relationships. Pharmacol Ther. 1992;53(1):67-79.